43rd week of 2017 patent applcation highlights part 9 |
Patent application number | Title | Published |
20170304263 | ANTIOXIDATIVE STRESS COMPOSITIONS, METHODS OF PREPARING AND USES THEREOF - Antioxidative stress compositions, methods of using antioxidative stress composition and methods of preparing antioxidative stress composition compositions are described. The antioxidative stress compositions may be chemopreventive and/or immunomodulatory. Resveratrol, genistein, ellagic acid, curcumin and quercetin may be included in the antioxidative stress composition compositions individually or in any combination. | 2017-10-26 |
20170304264 | Novel Erythromelalgia Treatment - The present invention is directed to the treatment of erythromelalgia comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof. | 2017-10-26 |
20170304265 | Paroxysmal Extreme Pain Disorder Treatment - The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof. | 2017-10-26 |
20170304266 | (3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration - The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof. | 2017-10-26 |
20170304267 | Use of an Acetylcholinesterase Inhibitor and Idalopirdine for Reducing Falls in Parkinson's Disease Patients - The present invention relates to the use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in patients suffering from a CNS disease, in particular patients with Parkinson's disease, wherein balance, gait or movement is impaired. | 2017-10-26 |
20170304269 | METHOD FOR TREATING NEURODEGENERATIVE DISEASES - The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration. | 2017-10-26 |
20170304270 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula I: | 2017-10-26 |
20170304271 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula I, | 2017-10-26 |
20170304272 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula I, | 2017-10-26 |
20170304273 | DYSLIPIDEMIA THERAPEUTIC AGENT - This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. | 2017-10-26 |
20170304274 | DYSLIPIDEMIA THERAPEUTIC AGENT - This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and nicotinic acid and nicotinic-acid amide, collectively referred to as niacin, an ester derivative thereof, a salt thereof, or a solvate of any of these. | 2017-10-26 |
20170304275 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY - The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations. | 2017-10-26 |
20170304276 | AN INHALABLE RAPAMYCIN FORMULATION FOR THE TREATMENT OF PULMONARY HYPERTENSION - The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof. | 2017-10-26 |
20170304277 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS - The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR-1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor. | 2017-10-26 |
20170304278 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE - The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders. | 2017-10-26 |
20170304279 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY - The invention provides a compound of Formula I, | 2017-10-26 |
20170304280 | SYNERGISTIC COMBINATIONS STIMULATING THE EXPRESSION OF SIRTUIN 1 - The invention discloses synergistic compositions stimulating the expression of Sirtuin comprising combinations of a first component selected from berberine and tyrosol with a second component selected from selected from quercetin, tyrosol, catechin and ferulic acid. | 2017-10-26 |
20170304281 | METHODS OF USING POTASSIUM CHANNEL INHIBITORS (BLOCKERS) FOR FLUID RESUSCITATION - Methods and pharmaceutical treatments of fluid resuscitation in which a selective potassium channel inhibitor is administered to a patient in a therapeutic amount sufficient to stabilize blood pressure and/or to reduce the amount of the resuscitation fluid otherwise required to resuscitate the patient. | 2017-10-26 |
20170304282 | FORMULATIONS OF AN LSD1 INHIBITOR - The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer. | 2017-10-26 |
20170304283 | COMPOUNDS AND COMPOUNDS FOR USE IN METHODS FOR TREATING DISEASES OR CONDITIONS MEDIATED BY PROTEIN DISULFIDE ISOMERASE - The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I). | 2017-10-26 |
20170304284 | Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging - This invention provides a nucleus-permeable small-molecule inhibitor, L | 2017-10-26 |
20170304285 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR - The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material. | 2017-10-26 |
20170304286 | NEW INDICATION OF PAROXETINE PHARMACEUTICAL COMPOSITION FOR TREATING CANCER - A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of Paroxetine or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer, osteosarcoma, skin cancer, and blood cancer. The pleural-related cancer is lung cancer. The abdominal-related cancer is selected from bladder cancer, cervical cancer, and kidney cancer. The endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer. The gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer. | 2017-10-26 |
20170304287 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING COMPLEX FORMULATIONS OF IVACAFTOR AND LUMACAFTOR AND THEIR SALTS AND DERIVATIVES, PROCESS FOR THEIR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Disclosed herein is a pharmaceutical combination composition comprising stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor and Lumacaftor, their salts, or derivatives thereof, which is useful in the treatment of cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease. More specifically, the pharmaceutical composition comprising the complexes possesses instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form. Further disclosed are methods of formulating and manufacturing said complexes, pharmaceutical compositions containing said complexes, and methods of treatment using said complexes and their pharmaceutical compositions. | 2017-10-26 |
20170304288 | Formulations of Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases - Provided herein are formulations and co-solvent formulations and methods for treating an infectious disease utilizing the same. The formulations and co-solvent formulations may comprise a hydroxyquinoline analog or its pharmaceutically acceptable salt, a solvent and at least two surfactants. Also provided are methods of quantitating a hydroxyquinoline analog in a sample via chromatographic/spectrometric measurements. | 2017-10-26 |
20170304289 | COMBINATIONS COMPRISING SIPONIMOD AND LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The present invention relates to combinations and pharmaceutical compositions comprising siponimod and laquinimod, and the use of said combinations and/or compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis. | 2017-10-26 |
20170304290 | QUINOLINE DERIVATIVE AGAINST NON-SMALL CELL LUNG CANCER - The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of lung adenocarcinoma, and relative to placebo, can significantly improve lung adenocarcinoma patients without progression of survival. | 2017-10-26 |
20170304291 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS - The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject. | 2017-10-26 |
20170304292 | Tetrahydroisoquinoline Derivatives - The present invention relates to tetrahydroisoquinoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role. | 2017-10-26 |
20170304293 | COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS - The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2017-10-26 |
20170304294 | USE OF NALMEFENE IN NON-ALCOHOLIC STEATOHEPATITIS - The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of NASH, NAFLD, and/or ASH. | 2017-10-26 |
20170304295 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE - Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided. | 2017-10-26 |
20170304296 | NOVEL PHARMACEUTICAL FORMULATION - The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of guaifenesin, naproxen and at least one further active which is selected to be an antitussive, a decongestant or an antihistamine. | 2017-10-26 |
20170304297 | IMMEDIATE RELEASE ABUSE DETERRENT TABLET - The invention relates to an abuse deterrent immediate release tablet. | 2017-10-26 |
20170304298 | COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS - This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed | 2017-10-26 |
20170304299 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS - The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I). | 2017-10-26 |
20170304300 | HIF-2alpha INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS - The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating iron overload disorders. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and reduced liver iron accumulation and serum iron parameters in both prophylactic and treatment mouse models. | 2017-10-26 |
20170304301 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION - The present invention relates to methods for treating | 2017-10-26 |
20170304302 | Compounds for Treatment of Cancer - The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer. | 2017-10-26 |
20170304303 | Novel Pyrimidinyl-DiazoSpiro Compounds - The invention relates to spiro deriviatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation. | 2017-10-26 |
20170304304 | THERAPEUTIC COMPOUNDS - The invention provides a compound of formula I: | 2017-10-26 |
20170304305 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF - The invention relates to quinazoline derivatives substituted by aniline which are represented by the below formula (I), pharmaceutical acceptable salts and stereoisomer thereof, wherein these groups of R | 2017-10-26 |
20170304306 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES - Provided herein are methods for treating or preventing prediabetes or diabetes, or maintaining or lowering blood or plasma glucose or maintaining or lowering blood or plasma glycated hemoglobin comprising administering to a subject in need thereof a therapeutically effective amount of a compound selectively inhibiting NaV1.7. In particular, provided herein are processes for the preparation of and intermediates used in the preparation of compounds selectively inhibiting NaV 1.7, such as the compounds of Formula I or compounds of Formula I′: | 2017-10-26 |
20170304307 | TOFACITINIB ORALLY DISINTEGRATING TABLETS - The present invention relates to Orally Disintegrating Tablets (ODT) of Tofacitinib and its pharmaceutically acceptable salts and the process to produce the ODT. The invention further relates to ODTs comprising Tofacitinib and its pharmaceutically acceptable salts, at least one sweetening agent, at least one disintegrant and optionally other excipients. The weight of the Orally Disintegrating tablets is 200 mg or less. The invention further relates to Orally Disintegrating Tablets of Tofacitinib Citrate. | 2017-10-26 |
20170304308 | Compositions and Methods for the Delivery of Therapeutics - The present invention provides compositions and methods for the delivery of antivirals to a cell or subject. | 2017-10-26 |
20170304309 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 - The present invention relates to caffeine for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising caffeine for use in the treatment of myotonic dystrophy type 1 and type 2. | 2017-10-26 |
20170304310 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 - The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels. | 2017-10-26 |
20170304311 | Pharmaceutical Combinations - A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof and (b) a gonadorelin agonist and, optionally, (c) an antiestrogen agent, particularly for use in the treatment or prevention of a cancer; uses of such a combination in the preparation of a medicament for the treatment or prevention of a cancer; pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a cancer in a subject comprising administering to said subject a therapeutically effective amount of such a combination. | 2017-10-26 |
20170304312 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,- 3-Thiazol-4-yl Amides - The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, | 2017-10-26 |
20170304313 | Therapeutic Combination For The Treatment Of Cancer - This invention relates to a pharmaceutical combination comprising (a) an EGFR inhibitor and (b) a FGFR inhibitor, particularly for use in the treatment of a cancer. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating or preventing a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto. | 2017-10-26 |
20170304314 | DOSAGE REGIMENT OF FERRIC MALTOL - The present invention relates to a dosage regimen of ST10 (ferric maltol) for use in the treatment of patients suffering from iron deficiency with or without anaemia. The invention specifically relates to use of ST10 wherein the dose is between 40 mg and 90 mg twice daily. | 2017-10-26 |
20170304315 | USE OF CDK9 AND BRD4 INHIBITORS TO INHIBIT INFLAMMATION - Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis. | 2017-10-26 |
20170304316 | Ophthalmic Solution - Disclosed herein an ophthalmic formulation comprises carbonic anhydrase inhibitor(s) alone, in an aqueous solution or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents and a manufacturing process thereof. | 2017-10-26 |
20170304317 | DIETARY SUPPLEMENTS FOR MUSCLE GROWTH AND STRENGTH - A compound is provided for oral administration of dehydroepiandrosterone (DHEA) derivatives to a human so as to improve at least one of adrenal hormonal balance, improved immune system function, reduction of adipose tissue, skeletal muscle growth, reduction of abdominal bloating, improved recovery from training, increased strength, and increased endurance. The compound includes a first portion comprised of any one of 3a-enanthoxy-5a-androstan-17-one, 3b-undecyloxy-5a-androstan-17-one, and 3b-hydroxy-androstane-3b-ol-one. A second portion of the compound is comprised of 6,7-dihydrogergamottin. A third portion is comprised of piperine, and a fourth portion is comprised of any one or more of rice flour, gelatin, magnesium stearate, and silica. The compound preferably is administered in capsule form one or two times in a 24-hour period. | 2017-10-26 |
20170304318 | 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS - The present invention provides certain cortexolone derivatives of formula (I) and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products. | 2017-10-26 |
20170304319 | DEXAMETHASONE ORAL FILM - The present invention relates to an oral film consisting essentially of dexamethasone and hydroxypropyl methylcellulose, wherein the concentration of dexamethasone is 30% w/w or more and the concentration of hydroxypropyl methylcellulose is between 35 and 70% w/w based on total dry matter. | 2017-10-26 |
20170304320 | EXTENDED-RELEASE DRUG DELIVERY COMPOSITIONS - An extended-release drug delivery composition and method of administering the same is provided. The composition comprises microspheres loaded with a biologically-active agent and suspended in a soluble polymer capable of forming a film upon injection onto a biological surface. | 2017-10-26 |
20170304321 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF - Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modulating compound, are provided. | 2017-10-26 |
20170304322 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS - The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating. | 2017-10-26 |
20170304323 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS - The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating. | 2017-10-26 |
20170304324 | METHOD FOR OBTAINING VITAMIN D2 FROM SHIITAKE MUSHROOMS - A method of obtaining vitamin D from shiitake includes a) adding ethanol to shiitake powder, followed by reflux extraction, to prepare a shiitake extract; and (b) irradiating ultraviolet (UV) light to the shiitake extract prepared in step (a). When shiitake extracts are obtained and exposed to ultraviolet light under specific conditions, the content of vitamin D2 in the shiitake extracts may be increased. | 2017-10-26 |
20170304325 | TREATMENT OF RHEUMATOID ARTHRITIS - A composition for treating chronic inflammation, including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D in synergistically effective amounts. A method of treating chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and treating chronic inflammation. A method of reducing and/or eliminating symptoms of chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and reducing and/or eliminating the individual's symptoms of chronic inflammation. | 2017-10-26 |
20170304326 | PHARMACEUTICAL COMPOSITION INCLUDING MIGRATORY FACTOR FOR GUIDING PLURIPOTENT STEM CELLS TO DAMAGE - The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient. | 2017-10-26 |
20170304327 | CANNABINOID RECEPTOR MODULATORS - Provided are certain methods useful in the treatment of cancer comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB | 2017-10-26 |
20170304328 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED CONTENT UNIFORMITY - This present invention relates to pharmaceutical compositions comprising cyclophosphamide alone and/or in combination with one or more pharmaceutical active ingredients and one or more pharmaceutically acceptable excipients wherein the cyclophosphamide has D90 particle size less than 100 microns. | 2017-10-26 |
20170304329 | METHODS OF BLADDER CANCER TREATMENT WITH CICLOPIROX, CICLOPIROX OLAMINE, OR A CICLOPIROX PRODRUG - A method of treating bladder cancer is provided. The method of treating bladder cancer can include: providing a pharmaceutical composition having ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug having a structure of one of the formulae provided herein or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the pharmaceutical composition to a subject having the bladder cancer. The ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug can be administered in a therapeutically effective amount. | 2017-10-26 |
20170304330 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS - The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer. | 2017-10-26 |
20170304331 | Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain - Osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome. | 2017-10-26 |
20170304332 | SUBSTITUTED BICYCLIC COMPOUNDS - Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): | 2017-10-26 |
20170304333 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES - Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars. | 2017-10-26 |
20170304334 | THERAPEUTIC MATERIAL FOR SKIN ULCER - It is an object to provide a therapeutic material for a skin ulcer which has excellent therapeutic effects on intractable skin ulcers such as decubitus ulcers with pockets and huge decubitus ulcers. By applying the therapeutic material for decubitus ulcers consisting of a fibrous material holding an antibiotic and a cell proliferation accelerator therein which is formed into an approximately spherical shape to a site of decubitus in a state in which a defect extending to the dermis, subcutaneous tissue, muscle or bone occurs, it is possible to treat critical skin ulcers such as intractable decubitus ulcers with pockets and huge intractable decubitus ulcers, as well as to treat not only relatively mild decubitus classified as stage II according to the US National Pressure Ulcer Advisory Panel (NPUAP) staging system, i.e., decubitus having ulcers in a state in which a part of the dermis is deficient, but also severe decubitus that has progressed to stage III to IV according to the NPUAP staging system, particularly decubitus with intractable ulcers with pockets or decubitus with huge intractable ulcers. | 2017-10-26 |
20170304335 | PHARMACEUTICAL COMPOSITIONS CONTAINING STEVIOSIDES - The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis. | 2017-10-26 |
20170304336 | COMBINATION - A combination comprising: (a) a glycyrrhizin derivative; and (b) a hypolipidemic drug; is disclosed. Pharmaceutical compositions, kits, methods of treatment and medical uses of the combination are also disclosed. | 2017-10-26 |
20170304337 | SILYL ETHERIFIED DERIVATIVES OF 5-AZACYTIDINES IN CARBOHYDRATE MOIETY - The present invention relates to a prodrug of 5-azacytidine or 2′-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2′-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, | 2017-10-26 |
20170304338 | USE OF NICOTINIC ACID RIBOSIDE OR NICOTINAMIDE RIBOSIDE DERIVATIVES, AND REDUCED DERIVATIVES THEREOF, AS NAD+ INCREASING PRECURSORS - Compositions are provided including nicotinic acid riboside (“NAR”), and derivatives thereof including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinic acid (“NAR triacetate” or “NARTA”); or derivatives of a reduced form of nicotinic acid riboside (“NARH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (“NARH triacetate” or “NARH-TA”); or derivatives of nicotinamide riboside (“NR”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinamide (“NR triacetate” or “NRTA”); derivatives of a reduced form of nicotinamide riboside (“NRH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinamide (“NRH triacetate” or “NRH-TA”); or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. Methods of using the compounds above to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (“NAD+”) or NADH in cells and tissues for improving cell and tissue survival or overall cell and tissue health are provided. | 2017-10-26 |
20170304339 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND DISORDERS CHARACTERIZED BY LYSOSOMAL DYSFUNCTION - The present invention relates to compositions and methods of treating lysosomal storage diseases and methods of using trehalose. | 2017-10-26 |
20170304340 | COMPOUND OF THE AVERMECTIN FAMILY OR OF THE MILBEMYCIN FAMILY FOR THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS - A method of treating and/or preventing atopic dermatitis is described. The method includes use of a compound of the avermectin family, possibly ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier. | 2017-10-26 |
20170304341 | METHODS FOR TREATING AND PREVENTING MUCOSITIS - Methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy, are disclosed herein. More specifically, disclosed herein is the administration of a therapeutically effective amount of at least one of an anthocyanoside, a proanthocyanidin, or an extract containing at least one of an anthocyanoside or a proanthocyanidin for the treatment or prevention of mucositis. The therapeutically effective amount of the anthocyanoside, proanthocyanidin or extract can be administered alone or in combination with a therapeutically effective amount of at least one of an anti-inflammatory agent, immunomodulating agent, analgesic, antimicrobial agent or antifungal agent. Also disclosed herein are pharmaceutical compositions for treating and preventing mucositis. | 2017-10-26 |
20170304342 | KNOTTIN-DRUG CONJUGATES AND METHODS OF USING THE SAME - Provided are knottin-drug conjugates. The conjugates include a knottin peptide that includes an engineered loop that binds to a target on a cancer cell surface, and a drug (e.g., a nucleoside drug) conjugated to the knottin peptide through a linker. Also provided are pharmaceutical compositions and kits that include the knottin-drug conjugates, as well as methods of using the knottin-drug conjugates, e.g., for therapeutic purposes. | 2017-10-26 |
20170304343 | BINDING PROTEINS SPECIFIC FOR LOX1 AND USES THEREOF - This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions. | 2017-10-26 |
20170304344 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS - The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: | 2017-10-26 |
20170304345 | PHARMACEUTICAL FORMULATIONS COMPRISING HIGH PURITY CANGRELOR AND METHODS FOR PREPARING AND USING THE SAME - The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation. | 2017-10-26 |
20170304346 | USE OF NADH OR SALT THEREOF IN PREPARATION OF DRUGS OR HEALTH-CARE PRODUCTS FOR TREATING PHENYLKETONURIA - Disclosed is use of nicotinamide adenine dinucleotide (NADH) or a salt thereof in the preparation of drugs or health-care products for treating phenylketonuria (PKU), wherein a single dose of the NADH or a salt thereof is 1-100 mg. | 2017-10-26 |
20170304347 | MICRORNA (miRNA) AND DOWNSTREAM TARGETS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES - In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis. | 2017-10-26 |
20170304348 | MiRNA and its Diagnostic and Therapeutic Uses in Diseases or Conditions Associated with Melanoma, or in Diseases or Conditions Associated with Activated BRAF Pathway - The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway. | 2017-10-26 |
20170304349 | DEFIBROTIDE FOR USE IN PROPHYLAXIS AND/OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) - Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (IISCT), more preferably allogeneic hernatopoietic stein cell transplantation. Graft versus Host Disease oldie invention (GVHD) can be acute aGVHD and/or chronic cOVHD, preferably acute. | 2017-10-26 |
20170304350 | PHARMACEUTICAL COMPOSITION FOR TREATING A VIRAL INFECTION - The invention concerns a pharmaceutical composition for treating a viral infection caused by a member of the Reoviridae family; a method of treatment involving the use of same and use of the anti-viral to treat said viral infection. The agent has use in both humans and animals. | 2017-10-26 |
20170304351 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION AND OTHER NON-INFECTIOUS DISEASES - The invention relates to methods, uses and compositions for treating non-infectious diseases with a therapeutically effective amount of a pharmaceutical composition comprising methylsulfonylmethane, glucosamine, L-glycine, and vitamin B | 2017-10-26 |
20170304352 | GLUCAN PREPARATIONS - Particulate β-glucan is solubilized at elevated pressure and temperature to form soluble β-glucan. The method is safe and economical and produces a product that is an improved pharmaceutical agent. | 2017-10-26 |
20170304353 | SLOWLY DIGESTIBLE, SUSTAINED-TYPE ENERGY SUPPLYING AGENT - An object of the present invention is to provide a carbohydrate-derived energy supplying agent having slow digestibility and sustained digestibility functions. According to the present invention, there is provided a slowly digestible, sustained-type energy supplying agent comprising a saccharide composition which satisfies the following (A), (B), (C), and (D): (A) a percentage of α-1,6 bonds relative to all glycosidic bonds is 60% or more; (B) a content of saccharides having a degree of polymerization of 1 and 2 relative to all saccharides is 9 mass % or less; (C) a content of saccharides having a degree of polymerization within a range of 3 to 30 relative to all saccharides is 41 mass % or more; and (D) a content of saccharides having a degree of polymerization of 31 or more relative to all saccharides is 50 mass % or less. | 2017-10-26 |
20170304354 | TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS - This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease. | 2017-10-26 |
20170304355 | COMPOSITIONS AND METHODS OF USE THEREOF - Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine. | 2017-10-26 |
20170304356 | METHOD FOR TREATING CONSTIPATION - The present invention provides a method of treating constipation and compositions useful in said method. The method comprises administering to a subject in need thereof an effective amount of a crosslinked carboxymethylcellulose having high elastic modulus coupled with high absorbance capacity when swollen in simulated gastric fluid/water (1:8) and simulated intestinal fluids. | 2017-10-26 |
20170304357 | NUTRACEUTICAL CONTAINING AN OXYGEN-ENABLED COMPOSITION - A composition of chlorine-free poly-oxygenated aluminum hydroxide that comprises a clathrate containing oxygen gas molecules and a nutraceutical. In one embodiment, the poly-oxygenated aluminum hydroxide has particles having a diameter of 212 μm or less. The nutraceutical may include one or more of a protein, vitamin, fiber, mineral and electrolytes. The composition may be in a powder or fluid form. | 2017-10-26 |
20170304359 | ORAL IODINE DOSAGE FORM - Provided is an oral dosage form comprising a deliverable form of iodine for treating symptoms related to fibrocystic breast condition, for prophylactically maintaining breast health, for treating fibrocystic breasts or breast cancer in pre-menopausal women, for prophylactically maintaining prostate health, and for treating benign prostate hyperplasia along with related methods for making and administering such dosage form. More particularly, this disclosure relates to an oral dosage form that is effective to deliver supraphysiologic levels of molecular iodine. The oral dosage form generally comprises a source of iodine and a reactive agent, wherein the source of iodine and/or the reactive agent are provided in excess. | 2017-10-26 |
20170304360 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM - Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual. | 2017-10-26 |
20170304361 | HALOGENATED INSULIN ANALOGUES OF ENHANCED BIOLOGICAL POTENCY - An insulin molecule comprises an Asp substitution at position B10, Glu at one or more of positions corresponding to A8, B28, and B29, and a halogenated phenylalanine at position B24. The analogue may optionally include (i) N-terminal deletion of one, two or three residues from the B chain, (ii) a mono-peptide or dipeptide C-terminal extension of the B-chain containing at least one acidic residue, and (iii) other modifications known in the art to enhance the stability of insulin. Formulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions at at least pH value in the range 7.0-8.0 in the absence or presence of zinc ions at a molar ratio of 0.00-0.10 zinc ions per insulin analogue monomer. A method of lowering the blood sugar level of a patient comprises administering a physiologically effective amount of the insulin to a patient. | 2017-10-26 |
20170304362 | MATERIALS AND METHODS TO ENHANCE HEMATOPOIETIC STEM CELLS ENGRAFTMENT PROCEDURES - This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE | 2017-10-26 |
20170304363 | COMPOSITIONS AND METHODS FOR TREATING VIRAL HEMORRHAGIC FEVER - The present disclosure provides compositions and methods for the treatment of viral hemorrhagic fever. The compositions and methods are useful for treating hemorrhagic fever virus infections and conditions associated with such infections. | 2017-10-26 |
20170304364 | NK-92 CELLS IN COMBINATION THERAPY WITH CANCER DRUGS - This disclosure is directed to compositions and methods for treating cancer using combination therapies of NK-92 cells with cancer drugs (e.g. thalidomide, cisplatin, and paclitaxel). | 2017-10-26 |